Nature of Disclosure: Regulatory filing to BSE and NSE containing the Outcome of the Board Meeting and the Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Board Meeting Details: The Board of Directors of Kopran Limited met on November 03, 2026. The meeting commenced at 11:00 AM and concluded at 1:30 PM. The Board, upon the recommendation of the Audit Committee, approved the Unaudited Standalone and Consolidated Financial Results for Q2 and H1 FY27, along with the Limited Review Reports from the Statutory Auditor.

Auditor's Review: The statutory auditor, Khandelwal Jain & Co. (Firm Regn. No.: 105049W), issued an unmodified review conclusion on both the standalone and consolidated results. They stated that based on their review, nothing has come to their attention that causes them to believe the statements contain any material misstatement. The review was conducted under SRE 2410 issued by ICAI.

Key Consolidated Financial Results (Q2 FY27 vs Q2 FY26):

  • Revenue from Operations: ₹21,126.25 Lakh (Prev. Yr: ₹11,790.93 Lakh)
  • Total Income: ₹21,188.61 Lakh (Prev. Yr: ₹11,793.49 Lakh)
  • Profit/(Loss) Before Tax: ₹589.29 Lakh (Prev. Yr: (₹1,162.63) Lakh)
  • Profit/(Loss) for the Period (Net Profit): ₹439.45 Lakh (Prev. Yr: (₹992.32) Lakh)
  • Total Comprehensive Income: ₹450.75 Lakh (Prev. Yr: (₹1,003.05) Lakh)
  • Basic & Diluted EPS: ₹0.91 (Prev. Yr: (₹2.06))

Key Consolidated Financial Results (H1 FY27 vs H1 FY26):

  • Revenue from Operations: ₹36,525.68 Lakh (Prev. Yr: ₹25,312.55 Lakh)
  • Total Income: ₹36,595.83 Lakh (Prev. Yr: ₹25,331.29 Lakh)
  • Profit/(Loss) Before Tax: ₹1,469.58 Lakh (Prev. Yr: (₹173.72) Lakh)
  • Profit/(Loss) for the Period (Net Profit): ₹1,109.54 Lakh (Prev. Yr: (₹247.39) Lakh)
  • Total Comprehensive Income: ₹1,131.78 Lakh (Prev. Yr: (₹281.37) Lakh)
  • Basic & Diluted EPS: ₹2.30 (Prev. Yr: (₹0.51))

Key Standalone Financial Results (Q2 FY27 vs Q2 FY26):

  • Revenue from Operations: ₹8,711.82 Lakh (Prev. Yr: ₹4,238.93 Lakh)
  • Total Income: ₹8,797.94 Lakh (Prev. Yr: ₹4,271.26 Lakh)
  • Profit/(Loss) Before Tax: ₹840.95 Lakh (Prev. Yr: (₹487.09) Lakh)
  • Profit/(Loss) for the Period (Net Profit): ₹628.56 Lakh (Prev. Yr: (₹399.34) Lakh)
  • Total Comprehensive Income: ₹636.32 Lakh (Prev. Yr: (₹411.00) Lakh)
  • Basic & Diluted EPS: ₹1.30 (Prev. Yr: (₹0.83))

Key Standalone Financial Results (H1 FY27 vs H1 FY26):

  • Revenue from Operations: ₹14,987.61 Lakh (Prev. Yr: ₹9,372.41 Lakh)
  • Total Income: ₹15,365.07 Lakh (Prev. Yr: ₹9,439.93 Lakh)
  • Profit/(Loss) Before Tax: ₹1,719.33 Lakh (Prev. Yr: (₹26.33) Lakh)
  • Profit/(Loss) for the Period (Net Profit): ₹1,300.86 Lakh (Prev. Yr: (₹47.53) Lakh)
  • Total Comprehensive Income: ₹1,316.38 Lakh (Prev. Yr: (₹70.86) Lakh)
  • Basic & Diluted EPS: ₹2.69 (Prev. Yr: (₹0.10))

Subsidiary Information in Consolidation: The consolidated results include the following subsidiaries:

1. Kopran Research Laboratories Limited

2. Kopran Lifesciences Limited (Management Certified)

3. Kopran (H. K) Limited

4. Kopran (UK) Limited (wholly owned subsidiary of Kopran Research Laboratories Limited)

The auditor's report notes reliance on other auditors for one subsidiary (Kopran Research Laboratories Ltd., with significant assets and income) and management certification for another (Kopran Lifesciences Ltd.). Two other subsidiaries were not reviewed by their auditors as they were deemed not material to the Group.

Share Capital: The paid-up equity share capital (face value ₹10 each) was ₹4,832.61 Lakh as of September 30, 2026, compared to ₹4,828.56 Lakh as of March 31, 2026.

ESOP Allotment: During the quarter, the company allotted 40,500 equity shares of ₹10 each (fully paid up) upon the exercise of stock options by employees under the Kopran Employee Stock Option Plan 2023.

Segment Information: The company and its subsidiaries (the Group) are primarily engaged in the Pharmaceuticals business. There are no separate reportable segments as per Ind AS 108.

Balance Sheet Highlights (Consolidated - Unaudited as of 30/09/2026 vs Audited as of 31/03/2026):

  • Total Assets: ₹96,378.28 Lakh (Prev: ₹90,836.24 Lakh)
  • Non-Current Assets: ₹40,937.18 Lakh (Prev: ₹38,518.57 Lakh)
  • Current Assets: ₹55,441.10 Lakh (Prev: ₹52,317.67 Lakh)
  • Total Equity: ₹52,797.12 Lakh (Prev: ₹53,028.05 Lakh)
  • Non-Current Liabilities: ₹5,167.90 Lakh (Prev: ₹3,190.18 Lakh)
  • Current Liabilities: ₹38,413.26 Lakh (Prev: ₹34,618.01 Lakh)

Cash Flow Highlights (Consolidated - H1 FY27 vs H1 FY26):

  • Net Cash from Operating Activities: (₹229.18) Lakh (Prev: ₹5,538.65 Lakh)
  • Net Cash used in Investing Activities: (₹3,216.04) Lakh (Prev: (₹3,356.54) Lakh)
  • Net Cash from Financing Activities: ₹3,449.53 Lakh (Prev: (₹1,077.85) Lakh)
  • Net Increase in Cash: ₹4.31 Lakh (Prev: ₹1,104.26 Lakh)

Notes: Figures for previous periods have been regrouped or reclassified wherever necessary for comparability. The financial results are prepared in accordance with Ind AS.